Increased serum osteoprotegerin level in older and diabetic hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 8, Issue 4, 2004, Pages 335-339

  Doi, Shigehiro ^a   Yorioka, Noriaki ^a,b   Masaki, Takao ^a   Ito, Takafumi ^a   Shigemoto, Kenichiro ^a   Harada, Satoru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Hemodialysis; Osteoprotegerin; Parathyroid hormone; Skeletal resistance

Indexed keywords

OSTEOPROTEGERIN; PARATHYROID HORMONE;

ADULT; AGE; AGED; ANALYTICAL PARAMETERS; ARTICLE; BONE DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SKELETON;

ADULT; AGED; AGED, 80 AND OVER; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PARATHYROID HORMONE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RENAL DIALYSIS;

EID: 4243068540     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-0968.2004.00159.x     Document Type: Article

References (18)

1. Monier-Faugere MC, Malluche HH. Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens 1997;6:327-32.
2. Gonzales EA. The role of cytokines in skeletal remodeling: possible consequences for renal osteodystrophy. Nephrol Dial Transplant 2000;15:945-50.
3. Herbelin A, Urena P, Ngyuyen AT. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991;39:954-60.
4. Montalban C, Garcia-Unzueta MT, DeFrancisco ALM. Serum interleukin-6 in renal osteodystrophy: relationship with serum PTH and bone remodeling markers. Horm Metab Res 1991;31:14-17.
5. Chambers TJ. Regulation of the differentiation and function of osteoclasts. J Pathol 2000;192:3-13.
6. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53.
7. Horwood NJ, Elliot J, Martin JM. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998;139:4743-6.
8. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-61.
9. Onya JE, Miles RR, Yang X. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 2000;15:863-71.
10. Ysuda H, Shima H, Nakagawa H et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclast inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:165-76.
11. Kazama JJ, Shigematu T, Yano K et al. Increased circulating levels of osteoclast inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-32.
12. Massry SG, Coburn JW, Lee DB, Jowsey J, Kleeman CR. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 1973;78:357-64.
13. Quarles LD, Lobau B, Murphy G. Intact parathyroid hormone overstimulates the presence and severity of parathyroid mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145-50.
14. Goodman WG, Ramirez JA, Belin TR et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994;46:1160-6.
15. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57.
16. Kazama JJ, Kato H, Sato T et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 2002;17:1860-1.
17. Sato T, Tominaga Y, Iwasaki Y et al. Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 2001;38:S175-7.
18. Simonet WS, Lacey DL, Dunstan CR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.